As CAR-T therapies mature and look to scale out, a current barrier exists between the number of patients in need of these therapies and highly skilled operator availability. In the United States, current capacity of operators and support staff for CAR-T development is estimated to be 12,000 while serving as many patients.
To reach potential and future demand, patients eligible for various advanced therapies could reach 20x this amount. Automation in biopharmaceuticals and cell therapy manufacturing addresses this gap, along with helping reduce the risk of contamination and ensures operator safety. CPC Biotech is providing innovative solutions by coupling sterile connectors with automated robotic systems for cell therapy manufacturing, removing the potential for human error and allowing for efficient scale up of the manufacturing process.
Key Takeaways:
Who should attend:
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.